A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (NCT07291076)

🧪 Interventions in This Study

• Pumitamig (DRUG)
• Ipilimumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (67 Sites)

Showing the first 25 of 67 sites.

• Local Institution - 0137 — Duarte, California
• Local Institution - 0070 — Los Angeles, California
• Local Institution - 0107 — Chicago, Illinois
• Local Institution - 0134 — Detroit, Michigan
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
• Local Institution - 0100 — Mineola, New York
• Providence Portland Medical Center — Portland, Oregon
• Providence St. Vincent Medical Center — Portland, Oregon
• Tennessee Oncology — Nashville, Tennessee
• Vanderbilt University Medical Center — Nashville, Tennessee
• Local Institution - 0083 — Seattle, Washington
• Royal Prince Alfred Hospital — Camperdown, New South Wales
• Local Institution - 0033 — Westmead, New South Wales
• Sunshine Coast University Hospital — Birtinya, Queensland
• The Royal Melbourne Hospital — Parkville, Victoria
• Bradfordhill — Santiago, Santiago Metropolitan
• Pontifica Universidad Catolica De Chile — Santiago Region Metropolitana, Santiago Metropolitan
• Local Institution - 0122 — Hefei, Anhui
• Local Institution - 0114 — Beijing, Beijing Municipality
• Local Institution - 0125 — Chongqing, Chongqing Municipality
• Local Institution - 0116 — Fuzhou, Fujian
• Local Institution - 0075 — Guangzhou, Guangdong
• Local Institution - 0129 — Nanning, Guangxi
• Local Institution - 0130 — Harbin, Heilongjiang
• Local Institution - 0128 — Nanyang, Henan

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hepatocellular Carcinoma (HCC)

• Streamlined Resin Y90 Radiation Segmentectomy for Small HCC — Chapel Hill, North Carolina
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE — Aurora, Colorado
• Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin — San Francisco, California
• Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. — Hamilton, Ontario
• Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant — London, Ontario
• Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 — Palo Alto, California

Explore by condition: All Hepatocellular Carcinoma (HCC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.